Home > Healthcare > Medical Devices > Therapeutic Devices > Lung Cancer Market

Lung Cancer Market Share

Report ID: GMI5417
Published Date: Jan 2023
Report Format: PDF

Download Free Sample

Lung Cancer Market Share

F. Hoffmann-La Roche
Thermo Fischer Scientific
Janssen Pharmaceuticals
Sanofi
Pfizer, Inc.
Qiagen
Quest Diagnostics

are some of the prominent enterprises in the lung cancer industry. The market is set to witness technological developments and product line extensions by industry participants to stay ahead in the competitive landscape. In December 2022, insight solutions provider QIAGEN N.V. broadened its product portfolio and client base by releasing a Tissue Companion Diagnostic. The FDA-approved assay is devised to Identify the KRAS G12C mutation in NSCLC Tumors, aiding the detection of non-small cell lung cancer (NSCLC).

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for lung cancer was worth over USD 29.5 billion in 2022 and is foreseen to grow significantly at over 11% CAGR through 2032 due to increasing initiatives undertaken by public & private organizations to raise disease awareness.

Diagnostics segment amassed over USD 14 billion in revenue in 2022 driven by the high prevalence of cancer, along with the growing focus of major players on finding innovative solutions for early diagnosis and treatment of lung cancer.

Europe lung cancer market is anticipated to exceed a valuation of USD 17 billion by 2032 owing to the widespread adoption of technologically advanced cancer diagnostic techniques and treatment.

F. Hoffmann-La Roche, Thermo Fischer Scientific, Janssen Pharmaceuticals, Sanofi, Pfizer, Inc., Qiagen, and Quest Diagnostics, among others are some of the leading firms operating in the lung cancer industry.